Mogrify

Mogrify has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY and epiMOGRIFY, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types...

Transmogrification,direct cellular conversion,stem cells,cell therapy,regenerative medicine,drug discovery,transcriptomics,big data,biotechnology,bioinformatics,machine learning,transdifferentiation,direct cellular reprogramming,cell reprogramming,gene therapy,cell and gene therapy,and in vivo reprogramming

Mogrify operates in the Biotechnology industry.

Mogrify's revenue is 11m - 100m

Mogrify has 11 - 50 employees.